

1 **Figure S1 Genetic architecture of the *cps* locus in *S. pneumoniae*.** (A) The locus
2 shown is representative of the Wzy-dependent capsule cassette of serotype 2. The
3 capsule locus, ~15 kb in size, is located between the conserved genes *dexB* and *aliA*
4 and is flanked on either side by insertion sequences (IS). *Cps2A-2D* are highly
5 conserved across most serotypes. Serotype-specific genes encode all enzymes
6 required to synthesize serotypespecific capsular polysaccharides. (B) Sequences of the
7 promoter for D39. The transcriptional start site for the promoter *P_{cps}* is assigned +1
8 and other positions are numbered accordingly. The initiation codon of *cps2A* is
9 indicated with an arrow. The primer pair of *P_{cps}-F* and *P_{cps}-R* is indicated with an
10 arrow underline, which is used to prepare C2 probe for DNA affinity
11 chromatography-pull down analysis.

12
13 **Figure S2 Isolating and identifying binding proteins to *cps* promoter.** (A)
14 SDS-PAGE analysis of *S. pneumoniae* cytoplasmic proteins fished out by affinity
15 chromatography using *cps* promoter DNA probe (C2) as bait. M, mass maker; Lane
16 c1 and c2 were eluted with NaCl at 100mM and 200mM under inducing conditions,
17 and lane k1 and k2, as blank magnetic beads control, respectively. Proteins were
18 stained with Coomassie Blue Staining. Numbers on the lane indicate the enriched
19 proteins excised and identified by MAIDI-TOF mass spectrometry. (B) The partial
20 MS result proteins that are most likely chosen to be further studied. (C) The
21 distribution of coverage rate of 24 proteins from the MS results. (D) Verifying the
22 specific binding ability of candidate proteins to *cps* promoter by EMSA *in vitro*. The
23 results showed that GntR, Tr-act, MarR, HU, 0410, and CcpA can bind specifically to *cps*
24 promoter, but non-phosphorylated ComE can bind hardly to it.

25
26 **Figure S3 Mimetic phosphorylated ComE.** (A) Shows the amino acid sequence of
27 ComE. The enriched protein from the 13 sample is identified as response regulator
28 ComE with 78.4% coverage rate by MALDI-TOF MS analysis. The consistent amino
29 acids sequence with MS is indicated with red italic underline text. (B) Phosphorylated
30 mimetic mutant ComE^{D58E} is constructed by site-directed mutagenesis of *comE* *in*

31 *vitro*. The molecular structure of mimetic site amino (Glu) is showed above the
32 nucleotide of comE. The site-directed mutagenesis nucleotide (G) and primer
33 sequence are indicated with box and red underline, respectively. (C)EMSA of
34 ComE^{D58E} binding to *cps* promoter sequence (C2 probe).The result shows that the
35 ComE^{D58E} exhibits significantly improved binding affinity for *cps* promoter sequence.
36

37 **Figure S4 The role of phosphorylation of ComE in regulating the CPS**
38 **production. (A)** Identification of D39ΔcomD、 D39ΔcomE、 D39ΔcomD::comE^{D58E}
39 and D39ΔcomE::comE^{D58E} mutants by PCR. **(B)** Detection of CPS production in D39
40 and its mutants by Western blot. GAPDH is detected as an internal control for
41 constitutively expressed gene. The ratio of gray values of each sample CPS to
42 GAPDH is calculated. The results of representative experiments are presented as
43 means of three replicates ± standard deviations. **, $P < 0.01$. **(C)** Neufeld test for
44 D39-WT and its mutants. The mean capsule thickness from 100 swelling cells is
45 measured with Image J software: D39-WT (0.4678±0.0985μm) 、 D39ΔcomE
46 (0.6271±0.1343μm) 、 D39ΔcomD (0.6530±0.1149μm) and
47 D39ΔcomD::comE^{D58E}(0.4778±0.0846μm).The statistical result shows that the
48 average swelling capsule thickness of D39ΔcomE mutant and D39ΔcomD are
49 significantly increased compared with that of D39-WT (**, $p < 0.01$). These results
50 indicate that the phosphorylation of ComE impact on the CPS production.

51
52





Figure S1 JPEG

53
54
55





Figure S2. JPEG

A

MKULILEDWIEHQVRLERILDEISKESNPISIKITGKUREFEFYIENDEVNQLYFLDDIHGEEKGFEVAQLRHYNPYAHVFTSRSEF
 ATLTYKIQVSAIDFVYDKDINDEMFKKRIEQNIIFYKSMLEENEDVYDIFDYNKGNDLKIPYHDILYIETTG' SHKLRUJGKNFAKEFY
 GTMTDIQEKDAHTQRFYSPHKSFLVYNGNREIDRKNLEIVFYEDHRCPISRKIRKRLKDIIEKKSQK

B



ATGAAA GTTTTAA TTTTGA A GAT GTTATT GAACATCAA GTGAGACTAGAGAGAATATTGGATGAAATT
 TCGAAA GAATCGAATATTTCCA ATATCATACAAGACAACGGGAAAA GTCCGTGAATTTGAAAGAATACAT
 TGAAA ATGATGAAAGTAAATCAGCTTTATTTCTAGAGATCGATATTCATGGAATTGAGAAAAAGGGATT
 TGAA GTGGCTCAGCTC ATTCGTCATTACAATCCTTACGCTATTATCGTCTTTATCACTAGTCGATCAGAG
 TTTGC GACTCTAAC ATATAA ATACCA GGTATCAGCCCTA GATTTT GTTGATAAGGATATCAATGATGAGA
 TGTTTAA GAA GAGA ATTGAGCAAAAATATCTTCTACACGAAAGATATGTTACTTGAAAATGAA GATGTT
 GTA GATTATTTTCGACTACAATTACAA GGGAA ATGATTTAAAAA ATTCCTTACC ATGATATTTTGTATATTG
 AAACAACA GGGGTATCTC ATAAAATTGCGCATTATTGGTAA GAAATTTGCAAAAAGAGTTTTATGGTACCA
 TGACAGATATTCAGGAAAAGGACAAAACATACTCAGCGATTTTATTCTCCTCACAAATCATTTTGGTAA
 ATATAGGCAATATCAGAGAAATTGATCGAAAAA ACTTAGAAAATTGTTTCTATGAA GACCATCGTTGTC
 CTATTTCAA GATTAAAAATTA GAAAATTA AAA GATATTTTA GAGAAAAAATCTCAAAA GTGA

C




Figure S3. JPEG




Figure S4. JPEG